

Supplementary Materials:

Circulating Tumour DNA is an Independent Prognostic Biomarker for Survival in Metastatic *BRAF* or *NRAS*-Mutated Melanoma Patients

Guillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, Sandrine Théoleyre, Gaëlle Quéréux, Cécile Frénard, Emilie Varey, Paul Hofman, Amir Khammari, Brigitte Dréno and Marc G. Denis




Figure 1. Kaplan-Meier estimates of Progression-Free Survival of patients treated in first line with targeted therapy (A) or immunotherapy (B). Kaplan-Meier estimates of Overall Survival of patients treated in first line with targeted therapy (C) or immunotherapy (D).




Figure 2. Kaplan-Meier estimates of Progression-Free Survival of *BRAF*-mutated patients (A) and *NRAS*-mutated patients (B). Kaplan-Meier estimates of Overall Survival of *BRAF*-mutated patients (C) and *NRAS*-mutated patients (D).